Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 2.1% – Time to Buy?
by Danessa Lincoln · The Markets DailyAtea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) traded up 2.1% during mid-day trading on Tuesday . The company traded as high as $4.55 and last traded at $4.48. Approximately 194,352 shares were traded during trading, a decline of 29% from the average session volume of 273,332 shares. The stock had previously closed at $4.39.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Atea Pharmaceuticals in a report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Atea Pharmaceuticals presently has a consensus rating of “Moderate Buy”.
Check Out Our Latest Research Report on AVIR
Atea Pharmaceuticals Stock Performance
The stock has a market capitalization of $348.13 million, a P/E ratio of -2.06 and a beta of 0.32. The firm has a fifty day moving average price of $4.83 and a two-hundred day moving average price of $4.56.
Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.03. On average, research analysts anticipate that Atea Pharmaceuticals, Inc. will post -1.93 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Atea Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in AVIR. Prudential Financial Inc. bought a new position in shares of Atea Pharmaceuticals in the 2nd quarter worth approximately $36,000. RFG Advisory LLC bought a new stake in Atea Pharmaceuticals during the fourth quarter valued at approximately $53,000. Quantinno Capital Management LP purchased a new stake in Atea Pharmaceuticals during the first quarter valued at approximately $86,000. Jump Financial LLC increased its holdings in Atea Pharmaceuticals by 36.5% during the fourth quarter. Jump Financial LLC now owns 19,113 shares of the company’s stock valued at $68,000 after buying an additional 5,106 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in Atea Pharmaceuticals in the fourth quarter worth approximately $69,000. Hedge funds and other institutional investors own 86.67% of the company’s stock.
About Atea Pharmaceuticals
Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.
Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.